NCT07528131Completed
18F-FDG PET/CT in Gastric Cancer
Role of 18F-FDG in Gastric Cancer
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
PET and PET/CT imaging remains promising, and with current and further improvements, PET and PET/CT imaging may make the diagnosis and evaluation of gastric cancer more standardized and accurate.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 7 Apr 2026
- Start date
- 22 Sept 2023
- Primary completion date
- 22 Sept 2024
- Lead sponsor
- Sohag University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07528131
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 22 Sept 2023 to the primary completion date, 22 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with second malignancy (Double primary).
- Patient without proven pathology of Cancer Stomach.
Lab values
- Uncontrolled diabetic patient with blood glucose level more than 200mg\\dl.
Other
- Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
- Pregnant women.
Who the study is looking for
- Patients diagnosed as Gastric Cancer on surgically resected specimens.
- Patients with gastric and extragastric metastasis.
- Patients with gastric cancer either operated or not
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sara Saber Ahmed Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.